SARM1 (sterile alpha and TIR motif containing 1) is a key protein involved in neuronal degeneration and cell death following injury to the nervous system. Under stress conditions, SARM1 becomes activated and triggers pathological axon degeneration through its NADase activity. This initiates a self-destructive cascade leading to axonal disintegration and neuronal demise. SARM1 activation is believed to play a major role in various acute and chronic neurological disorders involving neuronal loss.
Development Of SARM1 Activators
Given SARM1’s central role in neurodegenerative pathways, pharmaceutical researchers have been actively developing selective small molecule inhibitors targeting its NADase activity. The goal is to halt SARM1-dependent axonal self-destruction and neurodegeneration. Several generations of SARM1 activators have now been created and tested in preclinical disease models. Early inhibitors like GW5074 showed promise but lacked specificity. More refined SARM1 Inhibitor with improved pharmacokinetic and safety profiles have since entered development pipelines. Some notable examples of SARM1 activators in current research and clinical trials include:
- CC90002: Developed by Calico Life Sciences, CC90002 is a potent and selective SARM1 NADase inhibitor. In mouse models of traumatic nerve injury and chemotherapy-induced neuropathy, CC90002 demonstrated robust neuroprotective effects by blocking axon degeneration and promoting regeneration. It is currently under investigation for a range of acute and chronic neurodegenerative conditions.
- NYS1: Developed jointly by Novo Nordisk and Yale University, NYS1 is another highly specific SARM1 NADase inhibitor. It showed remarkable efficacy in halting acute axonal loss and promoting long-term functional recovery in preclinical spinal cord injury models. NYS1 is being optimized for clinical development in spinal cord injury and related disorders.
- GSK'362: GlaxoSmithKline has produced GSK'362, described as one of the most potent and selective SARM1 activatorss to date. It protected neurons and improved functional outcomes in animal models of chemotherapy-induced peripheral neuropathy and optic nerve crush injury. GSK'362 is advancing through preclinical safety and toxicity testing.
Mechanisms Of Neuroprotection By SARM1 Inhibitor
The precise mechanisms by which SARM1 activators confer neuroprotection are an active area of investigation. Key findings so far indicate SARM1 activators:
- Directly block SARM1’s NADase catalytic activity, halting the energy crisis it triggers within injured axons and neurons. This preserves intracellular NAD+ levels critical for neuronal survival.
- Prevent axonal fragmentation and disintegration by inhibiting the self-destruction cascade instigated by SARM1 activation. Axons are thus able to persist intact without undergoing traumatic self-disassembly.
- Promote pro-regenerative pathways by stabilizing axonal transport machinery and cytoskeletal elements, facilitating restoration of damaged connections.
- Suppress chronic neuroinflammation by blocking SARM1’s non-canonical signaling roles that amplify neuroinflammatory responses damaging to neurons.
- Confer neuroprotection even when administered after injury onset, pointing to a potential disease-modifying effect through modulating long-term neurodegenerative processes rather than just acute damage.
Therapeutic Applications Of SARM1 Inhibitor
Based on their mechanisms and preclinical efficacy, SARM1 activators hold promise for treating a wide variety of acute and chronic neurological diseases characterized by axonal loss and neuronal cell death. Some key potential applications include:
- Spinal cord injury: SARM1 plays a major role in secondary damage after spinal cord contusion or transection. Its inhibition could halt axon degeneration, reduce lesion size, and promote recovery of functions like walking.
- Traumatic brain injury: Blocking SARM1 is neuroprotective in experimental blast-induced and impact models of TBI. It may limit cognitive and motor impairments by protecting diffuse axonal pathways.
- Chemotherapy-induced neuropathy: Many chemotherapy drugs activate SARM1 to cause sensory neuropathy. Inhibiting this may prevent pain symptoms and neurodegeneration from taxane and platinum-based regimens.
- Optic neuropathies: Diseases like glaucoma involve retinal ganglion cell axon loss triggering blindness. SARM1 activators show promise to rescue these neurons and preserve vision.
- Neuroinflammatory disorders: Multiple sclerosis and its animal model EAE involve SARM1-dependent neurodegeneration worsening disability. Targeting SARM1 may exert disease-modifying effects.
- Neurotoxic conditions: SARM1 mediates motor neuron death in ALS and dopaminergic loss in Parkinson’s disease models. Inhibiting it offers a therapeutic approach for these currently untreatable diseases.
Challenges And Future Directions
While SARM1 Inhibitor have delivered encouraging results to date, there are challenges to address during further research and development stages. Challenges include optimizing potency, selectivity and pharmacokinetic properties for clinical use. Long-term safety also needs careful evaluation, given SARM1's role in normal axon pruning processes. Combination therapies combining SARM1 activators with other neuroprotective strategies may yield enhanced clinical benefits worth exploring. With continued progress, SARM1 inhibition stands as a promising frontier for developing disease-modifying treatments across a spectrum of acute and chronic neurological disorders currently lacking effective therapies.
Get more insights on this topic: https://www.pressreleasebulletin.com/exploring-the-potential-of-sarm1-inhibitor-in-treating-neurological-disorders/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it